Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
The association of primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) is thought to be rare, and its optimal treatment is unknown. Of 130 consecutive patients with a diagnosis of PBC, we identified 12 cases (9.2%) of overlap syndrome (10 females, 2 males; median age, 50 years) strictly defined by the presence of at least two of the three recognized biochemical, serological, and histological criteria of each disease. One patient had initially pure PBC and developed AIH characterized by a flare of alanine transaminase (ALT) (1,330 IU/L; N < 35), elevated immunoglobulin G (IgG) (42 g/L; N < 14.0), and presence of anti-smooth muscle antibodies (ASMA) after 20 months of ursodeoxycholic acid (UDCA) therapy. A complete clinical and biochemical remission was achieved under combination of corticosteroids and UDCA. Eleven patients had features of both diseases at presentation: high serum levels of alkaline phosphatase (AP) (median: 280 IU/L; N < 100), ALT (140 IU/L), and IgG (30.8 g/L), presence of mitochondrial antibodies (n = 9) or ASMA (n = 9), florid bile duct lesions (n = 8), and moderate or severe periportal or periseptal lymphocytic piecemeal necrosis (n = 11). UDCA (13-15 mg/kg/d) given alone in 5 patients induced a significant decrease in biochemical cholestasis but not in ALT levels, and liver fibrosis progressed in 3 patients. Corticosteroids given alone in 6 patients induced a significant decrease in ALT, IgG, and AP levels, but none had a biochemical normalization. The patients with persistently abnormal liver tests under either UDCA or corticosteroids received both UDCA and corticosteroids. A further marked biochemical improvement was observed, and all patients became asymptomatic. We conclude that, in patients with PBC: 1) overlap syndrome with AIH is not rare; 2) flares of AIH may occur either spontaneously or under UDCA; and 3) combination of UDCA and corticosteroids is required in most patients to obtain a complete biochemical response. Overlap syndrome may represent an important and unrecognized cause of resistance to UDCA in patients with PBC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The available data suggest that patients who fulfil the Paris criteria for the diagnosis of AIH either at presentation or during the course of their PBC may benefit from additional immunosuppression in the short-and medium-term [160,162,175,176].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [162]
In the citing paper
“A simplified AIH scoring system has more recently been developed, and, when applied to PBC patients, it identified fewer patients meeting probable AIH criteria than the older scoring system did (4% versus 12%).(125)(126)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [126]
In the citing paper
“Criteria have been proposed by the Paris group for ‘true’ PBC/AIH overlap,272 with two out of three of (a) ALT >5 x ULN, (b) IgG >2 x ULN or positive anti-SMA and (c) liver biopsy with ‘moderate or severe periportal or periseptal lymphocytic piecemeal necrosis (interface hepatitis)’ being suggested as diagnostic of overlap in the context of a PBC diagnosis.”
From The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines (2018) · cites this paper as [272]
Citations
Cites
An Algorithm for the Grading of Activity in Chronic Hepatitis C
Bedossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,088
Bedossa, P. (1994) · Hepatology · doi:10.1002/hep.1840200104 · Cited by 2,003
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Self-citationUrsodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Kaplan, M. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611213352107 · Cited by 455
Calmus, Y., Gane, P., Rouger, P., & Poupon, R. (1990) · Hepatology · doi:10.1002/hep.1840110104 · Cited by 303
Self-citationInvernizzi, P., Crosignani, A., Battezzati, P. M., Covini, G., De Valle, G., Larghi, A., Zuin, M., & Podda, M. (1997) · Hepatology · doi:10.1002/hep.510250507 · Cited by 293
Michieletti, P., Wanless, I. R., Katz, A., Scheuer, P. J., Yeaman, S. J., Bassendine, M. F., Palmer, J. M., & Heathcote, E. J. (1994) · Gut · doi:10.1136/gut.35.2.260 · Cited by 236
Research works printed but not linked: 2
- Shouval, 1979, Chronic active hepatitis with cholestatic features, Am J Gastroenterol, 72, 542
- Nakamura, 1995, Effect of ursodeoxycholic acid (UDCA) on patients with type 1 auto-immune hepatitis [Abstract], Gastroenterology, 107, 958A
Cited by
Items 501–600 of 743
Prevalence and clinicopathological Spectrum of Auto-Immune Liver Diseases & Overlap syndrome
Varadarajan, A., Rastogi, A., Maiwall, R., Bihari, C., Thomas, S. S., Sood, V., & Shasthry, S. M. (2023) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_72_22 · Cited by 3
Cançado, G. G. L., Gomes, N. M. D. F., Couto, C. A., Cançado, E. L. R., Terrabuio, D. R. B., Villela‐Nogueira, C. A., Braga, M. H., Nardelli, M. J., Faria, L. C., Oliveira, E. M. G., et al. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002744 · Cited by 3
Histological classification of autoimmune cholestatic liver diseases
Hübscher, S. G. (2000) · Springer eBooks · doi:10.1007/978-94-011-4000-3_20 · Cited by 4
Macaluso, F. S., Alessi, N., & Cabibi, D. (2012) · Hepatology Research · doi:10.1111/j.1872-034x.2011.00931.x · Cited by 3
Mitra, S., & Minz, R. W. (2016) · International Journal of Surgical Pathology · doi:10.1177/1066896916657643 · Cited by 5
“A diagnosis of an overlap syndrome should always be entertained once a diagnosis of any form of AILD is made and therefore a possibility of an overlap should either be diagnosed or refuted.(1-3,16,17) The diagnostic criteria of AIH-PBC overlap syndrome proposed by Chazouilleres et al is in vogue and takes into conside…”
BackgroundShin, W. Y., Suh, K., Kim, T., Jeon, Y. M., Yi, N., & Lee, K. U. (2010) · The Korean Journal of Hepatology · doi:10.3350/kjhep.2010.16.2.168 · Cited by 3
Recent developments in the management of idiopathic cholestatic liver disease.
Imam, M. H., Weeding, E., & Lindor, K. D. (2012) · PubMed Central · Cited by 3
Primary Biliary Cirrhosis: Autoimmune Hepatitis Overlap Syndrome
Iezzoni, J. C. (2010) · Pathology Case Reviews · doi:10.1097/pcr.0b013e3181df4334 · Cited by 3
Cristoferi, L., Nardi, A., Invernizzi, P., Mells, G. F., & Carbone, M. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.006 · Cited by 4
Amyotrophic Lateral Sclerosis and Primary Biliary Cirrhosis Overlap Syndrome: Two Cases Report
Zhang, H., Liu, Y., Li, Z., Liang, N., Zhou, X., Nie, X., Zhang, T., & Qi, W. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00890 · Cited by 4
“One study showed that PBC patients with overlapping characteristics of autoimmune hepatitis (AIH) would progress rapidly to cirrhosis and liver failure (21).”
BackgroundSherlock, F. S., & BSc, J. D. (2001) · Wiley eBooks · doi:10.1002/9780470986820.ch14 · Cited by 3
Bergasa, N. V. (2021) · Springer eBooks · doi:10.1007/978-1-4471-4715-2_4 · Cited by 3
Beuers, U. H., & Rust, C. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-518-3_23 · Cited by 3
“Single cases have been described in which the diagnosis of autoimmune liver disease changed during the long-term course, and transitions from PBC to AIH (4,5) as well as from AIH to PSC (6) have been described.”
BackgroundRe-analysis of patients with autoimmune hepatitis using simplified diagnostic criteria
Katsushima, F., Abe, K., Yokokawa, J., Monoe, K., Kanno, Y., Takahashi, A., & Ohira, H. (2009) · Kanzo · doi:10.2957/kanzo.50.618 · Cited by 3
Ursodeoxycholic acid and primary biliary cirrhosis with features of autoimmune hepatitis
Chazouillères, O., & Poupon, R. Y. (2002) · Hepatology · doi:10.1053/jhep.2002.34853 · Cited by 3
“5,6 (2) The question raised by the PBC patients with interface hepatitis but not fulfilling criteria of AIH as defined above is totally different.”
BackgroundSelf-citationHépatites auto-immunes: aspects physiopathologiques, cliniques, histologiques et thérapeutiques
Duclos‐Vallée, J., Samuel, D., Sebagh, M., Yamamoto, A., & Johanet, C. (2006) · EMC - Hépatologie · doi:10.1016/s1155-1976(02)00050-5 · Cited by 3
Adeyi, O. A. (2023) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2023.152185 · Cited by 3
Reversible Hepatic Decompensation in Primary Biliary Cirrhosis Due to Hypercoagulability
Lee, H. M., Amin, M. G., Kaplan, M. M., & Herlihy, E. F. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-9-200711060-00024 · Cited by 2
Mayo, M. J., & Thiele, D. L. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch100 · Cited by 2
sajadi, S. M. J., Tamizifar, B., Sanei, M. H., & Babak, A. (2024) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_813_22 · Cited by 2
Sebode, M., Bantel, H., Baumann, U., Bufler, P., Demir, M., Dold, L., Keitel, V., Klein, R., Kremer, A. E., Jansen, P. L., et al. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2769-2475 · Cited by 2
Tan, J. J.-R., Thiyagarajan, S., Tan, J., Ong, J., Lin, K., Tee, C. H. N., Tan, C. K., Tan, A. G. S., Ang, D., Ang, T. L., et al. (2026) · Canadian Liver Journal · doi:10.3138/canlivj-2026-0019 · Cited by 2
Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient
Abhyankar, A., Tapper, E. B., & Bonder, A. (2013) · Pharmaceuticals · doi:10.3390/ph7010018 · Cited by 3
“at least twice the upper limit of normal, (ii) positive AMA, and (iii) a liver biopsy showing florid bile duct lesion and AIH defined by (i) alanine transaminase levels at least five times the upper limit of normal, (ii) Immunoglobulin G levels at least twice the upper limit of normal or a positive anti-SMA, and (iii)…”
BackgroundMitra, S. (2012) · Gastroenterology Research · doi:10.4021/gr485w · Cited by 2
“5mg/kg) for complete biochemical remission and arrest of progression of bridging fibrosis [6, 16].”
BackgroundMethodCorrigan, M., & Hirschfield, G. M. (2016) · Frontline Gastroenterology · doi:10.1136/flgastro-2016-100698 · Cited by 3
Primary Biliary Cholangitis- Autoimmune Hepatitis Overlap Syndrome
Bhatt, P., Gupta, D. K., Ramani, N., Tibdewal, P., Sadalage, A., Agrawal, D., Joshi, A., & Shukla, A. (2018) · The Indian Journal of Pediatrics · doi:10.1007/s12098-018-2628-x · Cited by 2
“Patient fulfilled Paris criteria for PBC and AIH, required for diagnosis of overlap syndrome [2].”
MethodThe Pathogenesis of Autoimmune Liver Diseases
Kovalic, A. J., & Bonkovsky, H. L. (2020) · Springer eBooks · doi:10.1007/978-3-030-33628-8_2 · Cited by 3
Tanaka, A., Leung, P. S. C., Bowlus, C. L., & Gershwin, M. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-51709-0_22 · Cited by 2
Tanaka, A., & Gershwin, M. E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812102-3.00058-0 · Cited by 2
Zarachi, A., Pelechas, E., Tsikou, A., Kalambokis, G. N., Zioga, A., Panteli, K. E., Rapti, I., Filippas-Ntekouan, S., Kastanioudakis, I. G., & Karassa, F. B. (2022) · Mediterranean Journal of Rheumatology · doi:10.31138/mjr.33.3.349 · Cited by 2
Zen, Y., Hübscher, S. G., & Nakanuma, Y. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8228-3.00009-0 · Cited by 3
Sorrentino, M. C., SIPMeL, A. N. D. G.-A., Carbone, T., Cinquanta, L., Alessio, M. G., Infantino, M. G., Deleonardi, G., TREVISAN, M. T., Porcelli, B., Terzuoli, L., et al. (2024) · La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine · doi:10.23736/s1825-859x.24.00226-3 · Cited by 2
Souissi, S., Laabidi, S., Mustapha, N. B., Chelly, I., Serghini, M., Fekih, M., Laabidi, A., & Boubaker, J. (2024) · Future Science OA · doi:10.2144/fsoa-2023-0187 · Cited by 2
Inborn Errors of Immunity in Adults with Autoimmune Liver Diseases
Ayar, Ş. N., Aytekin, E. S., Şimşek, C., Dağ, O., Cağdaş, D. N., & Balaban, Y. H. (2024) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2024.23171 · Cited by 2
Autoimmune Cholangitis: Not Just AMA-negative Primary Biliary Cirrhosis
Washington, K. M. (2002) · Advances in Anatomic Pathology · doi:10.1097/00125480-200207000-00004 · Cited by 2
“Others have concluded that overlap of PBC and AIH is not rare, and that combination therapy with UDCA and steroids is indicated in most of these patients to obtain a biochemical response (8).”
BackgroundInfluentialMackay, I. R. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-374994-9.10046-4 · Cited by 2
Mallet, V. O., Corouge, M., & Sogni, P. (2013) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(13)71853-7 · Cited by 3
Spengler, U. (2010) · Die Gastroenterologie · doi:10.1007/s11377-009-0390-3 · Cited by 2
[Autoimmune hepatitis and primary sclerosing cholangitis: dependent or independent association?].
Guerrero-Hernández, I., Montaño‐Loza, A. J., Gallegos-Orozco, J. F., & Weimersheimer-Sandoval, M. (2007) · PubMed · Cited by 2
Hagymási, K., & Tulassay, Z. (2013) · Orvosi Hetilap · doi:10.1556/oh.2013.29640 · Cited by 2
Nguyen-Khac, É., Kairis, L., Gournay, N., Bonnière, M., Thévenot, T., Mathurin, P., HACHULLA, E., Paris, J.-C., & Dupas, J. (2004) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(04)95189-5 · Cited by 2
“[25] avaient identifié 12 overlap syndromes, soit une fréquence de 9,2 %.”
BackgroundInfluentialIwata, M., Iwata, M., Sasaki, M., Harada, K., Kaneko, S., KOBAYASHI, K. P., Adachi, K., Sasaki, M., & Nakanuma, Y. (2001) · Pathology - Research and Practice · doi:10.1078/0344-0338-00011 · Cited by 2
Primary biliary cirrhosis with features of autoimmune hepatitis
Heathcote, J. (2001) · Current Gastroenterology Reports · doi:10.1007/s11894-001-0042-3 · Cited by 2
Mahfoudhi, M., Mamlouk, H., Sami, T., & Adel, K. (2015) · Open Journal of Clinical Diagnostics · doi:10.4236/ojcd.2015.51004 · Cited by 2
“[14] are specific, but their sensitivity is not demonstrated.”
BackgroundCase of Primary Biliary Cirrhosis-Autoimmune Hepatitis Overlap which Manifested after Delivery
Monoe, K., Takahashi, A., Katsushima, F., Kanno, Y., Saito, H., Abe, K., Yokokawa, J., & Ohira, H. (2011) · Internal Medicine · doi:10.2169/internalmedicine.50.5022 · Cited by 2
“proposed the diagnostic criteria for PBC-AIH overlap that are now widely accepted (13).”
BackgroundKim, M. S., Kim, Y. S., Kim, S. G., Byun, J. M., Yoon, L. Y., Han, D., Moon, J. J., Nam, J.-H., Kim, T. J., Lee, S. H., et al. (2013) · Korean Journal of Medicine · doi:10.3904/kjm.2013.84.2.211 · Cited by 2
“현재 중복증후군은 아직까지 진단방법이 표준화되어 있지 못하며, 흔히 사용되고 있는 Paris criteria [12]의 경우 Kuiper 등[13]에 의해 이루어진 후향적, 단일기관 연구를 통해 각각 92%와 97%의 민감도와 특이도가 보고되었지만, 적절성을 입증하기 위한 더 많은 연구가 필요한 상태이다.”
五十嵐悠一, Taniai, M., Hashimoto, E., Kodama, K., Kogiso, T., Torii, N., & Tokushige, K. (2016) · Kanzo · doi:10.2957/kanzo.57.97 · Cited by 2
Zamor, P. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-33628-8_10 · Cited by 2
Sclair, S. N., & Levy, C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-37591-7.00042-2 · Cited by 3
(2017) · Elsevier eBooks · doi:10.1016/b978-0-323-44307-4.50044-0 · Cited by 2
Levy, C., Carrion, A. F., & Mayo, M. J. (2017) · Wiley eBooks · doi:10.1002/9781119251316.ch21 · Cited by 2
Cole, C. D., & Saxena, R. (2013) · Surgical pathology clinics · doi:10.1016/j.path.2013.03.003 · Cited by 2
Biologie des Maladies Cholestatiques Chroniques de l' Adulte
Chazouillères, O. (2007) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(07)80301-7 · Cited by 2
Self-citationPathologic features and differential diagnosis of chronic hepatitis
Choi, W., & Gill, R. M. (2022) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2022.10.003 · Cited by 3
Liver Involvement in Sjögren’s Syndrome
Fragoulis, G., Skopouli, F. N., Selmi, C. F., & Gershwin, M. E. (2011) · Springer eBooks · doi:10.1007/978-0-85729-947-5_17 · Cited by 4
Methotrexate for Primary Biliary Cirrhosis: Who Is to Be Trusted?
Selmi, C. F., & Podda, M. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1435-7 · Cited by 2
“Of note, the subgroup of patients with incomplete response to UDCA had no distinguished clinical features, although we noted a higher prevalence of interface hepatitis at histology [17].”
BackgroundOverlap syndromes from pediatrics to adulthood
Bogdanos, D. P., Vergani, D., & Mieli‐Vergani, G. (2004) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2004.03688.x · Cited by 2
Efe, C., Pürnak, T., & Özaslan, E. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.04.007 · Cited by 2
Czaja, A. J. (1999) · Current Opinion in Gastroenterology · doi:10.1097/00001574-199905000-00009 · Cited by 2
Liberal, R., Mieli‐Vergani, G., & Vergani, D. (2020) · Springer eBooks · doi:10.1007/978-3-030-51709-0_26 · Cited by 1
Cazzagon, N., & Chazouillères, O. (2021) · Springer eBooks · doi:10.1007/978-3-030-65908-0_11 · Cited by 1
Self-citationMicroorganisms in Pathogenesis and Management of Autoimmune Hepatitis (AIH)
Upadhyay, T., & Bhatt, S. (2022) · Springer eBooks · doi:10.1007/978-981-19-1946-6_5 · Cited by 1
Barbosa, B. R., Pereira, L., Campante, F., & Pona, A. P. (2024) · Cureus · doi:10.7759/cureus.51630 · Cited by 2
“Combining UDCA and corticosteroids has been suggested to have a synergistic effect [18].”
BackgroundCo-occurrence of autoimmune liver disease and gallstones: a clinically overlooked phenomenon
Hu, Y., Liu, M., Shu-qian, L., Ji, Y., Su, Y., Yang, J., Zhang, X., Zhou, S., Guo, L., Li, Y., et al. (2025) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002978 · Cited by 1
Ruiu, A., Calabrese, M. P., Meschisi, P., Plebani, R., Maria, B., Lleò, A., & Ronca, V. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106883 · Cited by 1
“Overlap” Syndromes in Autoimmune Liver Disease
Tzadok, R., & Houri, I. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.04.008 · Cited by 1
Sirirattanakorn, S., Suttichaimongkol, T., Manasirisuk, W., Sawadpanich, K., Sangchan, A., Mairiang, P., Sukeepaisarnjaroen, W., & Rattananukrom, C. (2026) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2026.103589 · Cited by 1
Syndrome de chevauchement entre hépatite auto-immune – cirrhose biliaire primitive
Safer, L., Chaabane, N. B., Brahmi, I., & Saffar, H. (2004) · La Presse Médicale · doi:10.1016/s0755-4982(04)99002-1 · Cited by 1
Primary biliary cirrhosis and sclerosing cholangitis
Portmann, B. C. (2002) · Current Diagnostic Pathology · doi:10.1054/cdip.2002.0011 · Cited by 1
A case of primary biliary cholangitis overlapping with type 2 autoimmune hepatitis
Amano, N., Sato, S., Murata, A., Tsuzura, H., Tomishima, K., Sato, S., Matsumoto, K., Shimada, Y., Iijima, K., Harada, K., et al. (2019) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-019-01017-2 · Cited by 1
Autoimmune Hepatitis and Overlap Syndromes
Janmohamed, A., & Hirschfield, G. M. (2018) · Wiley eBooks · doi:10.1002/9781119237662.ch19 · Cited by 1
INCIDENCE OF AUTOANTIBODIES IN PATIENTS WITH AUTOIMMUNE LIVER DISEASES AND CHRONIC HEPATITIS C
Raikhelson, K. L., Мительглик, У. А., Зубарева, А. С., Дунаева, Н. В., Булгакова, Т. В., Lapin, S. V., Baranovsky, A. Y., & Areg, A. T. (2014) · Medical Immunology (Russia) · doi:10.15789/1563-0625-2013-4-351-360 · Cited by 1
Differential diagnosis of human hepatitis
Sprinzl, M. F., & Galle, P. R. (2008) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8558-3_2 · Cited by 1
Wendum, D. (2008) · Annales de Pathologie · doi:10.1016/j.annpat.2008.09.014 · Cited by 1
Self-citationJohanet, C., & Ballot, E. (2004) · Bio Tribune Magazine · doi:10.1007/bf03000521 · Cited by 1
Martínez, Ó. N., Ibáñez, I. M., Bravo-Burguillos, E. R., Sotillos, A. E., & Sosa, J. C. E. (2012) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2012.07.007 · Cited by 1
Takada, K., Kato, J., 訓博, 高., Kawano, Y., 敏徳, 奥., Hayashi, T., Ishiwatari, H., Takahashi, S., Miyanishi, K., 康史, 佐., et al. (2006) · Kanzo · doi:10.2957/kanzo.47.304 · Cited by 1
Hou, J. K., Gershwin, M. E., Green, L., & Yoffe, B. (2009) · BMJ Case Reports · doi:10.1136/bcr.08.2008.0767 · Cited by 1
Current progress in our understanding of cholestasis and chronic cholestatic disorders
Papatheodoridis, G. (2007) · Annals of Gastroenterology · Cited by 1
Hirae, M., Watanabe, T., Yoshimaru, Y., Kawasaki, T., Izumi, K., Mizobe, N., Fukubayashi, K., Tateyama, M., Tanaka, M., Iyama, K., et al. (2014) · Kanzo · doi:10.2957/kanzo.55.176 · Cited by 1
Samat, M. N. A., Wahab, A. A., Ding, C. H., Mohammad, M., Biswas, S., & Rahman, M. M. (2015) · EXCLI journal · doi:10.17179/excli2014-660 · Cited by 1
“Combination treatment of glucocorticoids and UDCA is effective in improving liver histology within seven years of follow-up in patients conforming to a strictly defined PBC-AIH overlap syndrome, as opposed to UDCA or corticosteroids alone (Chazouillères et al., 1998).”
BackgroundA case of PBC-AIH overlap syndrome who developed AIH 8 years after diagnosis of typical PBC
Sasaki, R., Akiyama, M., Takeshita, S., Miuma, S., Ozawa, E., Miyaaki, H., Ichikawa, T., Nakao, K., TORIYAMA, H., & Eguchi, K. (2009) · Kanzo · doi:10.2957/kanzo.50.445 · Cited by 1
Primary Biliary Cholangitis: Its Science and Practice
Wang, L., Bowlus, C. L., Wang, F., & Gershwin, M. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-50168-0_8 · Cited by 2
Kaneko, A., Tatsumi, T., Yakushijin, T., Hiramatsu, N., Mita, E., Nakanishi, F., Oshita, M., Yoshihara, H., Imai, Y., Fukui, H., et al. (2015) · Kanzo · doi:10.2957/kanzo.56.507 · Cited by 1
Tesfaldet, B., Csákó, G., Patel, T. M., Shamsuzzaman, M., & Almario, E. N. (2018) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-7677-5_21 · Cited by 2
Kakar, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-42873-6.00026-3 · Cited by 2
Cristoferi, L., Nardi, A., Invernizzi, P., Mells, G. F., & Carbone, M. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.08.007 · Cited by 1
Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis
Ahn, D. (2020) · The Korean Journal of Pancreas and Biliary Tract · doi:10.15279/kpba.2020.25.2.107 · Cited by 1
An Interesting Case of Autoimmune Liver Disease
Kathuria, P., Arora, S. K., Karna, R., Kumar, N. P., Kumar, S., V, & Kar, P. (2020) · Annals of the National Academy of Medical Sciences (India) · doi:10.1055/s-0040-1722105 · Cited by 1
Primary biliary cholangitis‐autoimmune hepatitis overlap syndrome: Case report and literature review
Razafindrazoto, C. I., Rakotozafindrabe, A. L. R., Randriamifidy, N. H., Rasolonjatovo, A. S., Rabenjanahary, T. H., Razafimahefa, S. H., & Ramanampamonjy, R. M. (2021) · Clinical Case Reports · doi:10.1002/ccr3.3861 · Cited by 1
AUTOIMMUNE CHOLESTATIC LESIONS OF BILIARY DUCTS
Tsyrkunov, V. M., Прокопчик, Н. И., & Андреев, В. П. (2021) · Hepatology and Gastroenterology · doi:10.25298/2616-5546-2021-5-2-99-110 · Cited by 1
“ПСХ), называемых синдромами перекрытия или перехлеста (overlap syndrom) и относящихся к наиболее тяжелым диффузным холестатическим поражениям печени [28-30].”
Zhou, M., Cheng, C., Han, Y., Huang, Y., Niu, M., He, X., Liu, Y., Xiao, X., Wang, J., & Ma, Z. (2022) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2022-0147 · Cited by 1
Autoimmune Hepatitis and Overlap Syndromes
Hirschfield, G. M., & Heathcote, E. J. (2011) · Wiley eBooks · doi:10.1002/9781444341294.ch23 · Cited by 1
Krawitt, E. L. (2011) · Wiley eBooks · doi:10.1002/9781119950509.ch22 · Cited by 1
Approach to the liver biopsy diagnosis of adult cholangiopathies
Nalbantoglu, I., & Misdraji, J. (2022) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2022.10.004 · Cited by 1
Holistic Patient Care in Primary Biliary Cholangitis: Managing Both the Disease and the Symptoms
Roberts, E. (2022) · EMJ Hepatology · doi:10.33590/emjhepatol/10166227 · Cited by 1
Çetinkaya, N. S., Cengiz, M., & Aydın, E. G. (2023) · Gulhane Medical Journal · doi:10.4274/gulhane.galenos.2023.66376 · Cited by 1
Li, M., Chen, S., Li, S., Lv, T., Li, B., Shan, S., Li, M., Zeng, N., Wang, Q., Kong, Y., et al. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231224840 · Cited by 2
“7,9,25,26 This might be because Chinese patients with PBC usually have only mild elevation of transaminase and IgG levels, a lower SMA positive rate, and a lower proportion of patients who receive liver biopsy.”
BackgroundPolpichai, N., Saowapa, S., Chan, S., Wattanachayakul, P., Danpanichkul, P., Fangsaard, P., & Trongtorsak, A. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002791 · Cited by 1
“Chazouillères et al. [29] proposed a strict diagnostic criterion for AIH and found that overlapping cases of PBC-AIH were observed in 12 of 130 patients (9.2”
InfluentialTrivella, J. P., & Levy, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-26710-9.00018-3 · Cited by 1
Metadata
- Authors
- Chazouillères, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., & Poupon, R.
- Affiliations
- Assistance Publique – Hôpitaux de Paris (FR)
- Corresponding author
- Chazouillères, Olivier
- Venue
- Hepatology
- Published
- 1998-08
- Volume
- 28
- Issue
- 2
- Pages
- 296-301
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2056147648
- Semantic Scholar
- e5878dda2aeaf614ad753e5c66ea3a752edfb605
- Cited by
- 746
- References
- 34
- Citations by year
- 2026: 21 · 2025: 29 · 2024: 37 · 2023: 37 · 2022: 32 · 2021: 31 · 2020: 31 · 2019: 27 · 2018: 38 · 2017: 31 · 2016: 28 · 2015: 36 · 2014: 32 · 2013: 32 · 2012: 33
- FWCI
- 12.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 6240 d)
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- primary biliary cirrhosis, autoimmune hepatitis, overlap syndrome, ursodeoxycholic acid, corticosteroids, combination therapy, treatment resistance, anti-smooth muscle antibodies, antimitochondrial antibodies, cholestasis, liver fibrosis, IgG, anti-amyloid antibodies, remission, disease flares, bile duct lesions
- MeSH terms
- Adrenal Cortex Hormones, Adult, Aged, Cholagogues and Choleretics, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Liver Cirrhosis, Biliary, Male, Middle Aged, Syndrome, Ursodeoxycholic Acid, Treatment Outcome, Hepatitis, Autoimmune
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.